TimesSquare Capital Management LLC Purchases Shares of 157,327 Kymera Therapeutics, Inc. $KYMR
TimesSquare Capital Management LLC acquired a new stake of 157,327 shares in Kymera Therapeutics, Inc. ($KYMR) during the second quarter, valued at approximately $18 million. Despite significant insider selling totaling $387.6 million over the past three months, analysts maintain a "Moderate Buy" rating with a consensus price target of $125.65. Kymera Therapeutics also surpassed quarterly earnings expectations, reporting a smaller adjusted loss and a substantial revenue increase year-over-year.
Kymera Therapeutics, Inc. $KYMR Shares Sold by Bank of America Corp DE
Bank of America Corp DE reduced its stake in Kymera Therapeutics (NASDAQ:KYMR) by 14.6% in the first quarter, selling 49,583 shares but retaining 289,416 shares valued at $24.1 million. Despite this, Kymera Therapeutics shares opened higher, up 3.4%, after reporting better-than-expected quarterly results with a loss of $0.62 per share and revenue up 465.2% year over year. The stock maintains a "Moderate Buy" consensus from analysts with an average price target of $125.65, though company insiders sold approximately $387.6 million in shares during the latest quarter.
Kymera Therapeutics Stock Rockets 17% With 9-Day Winning Streak
Kymera Therapeutics (NASDAQ: KYMR) stock surged by 17% and recorded a nine-day winning streak. The article provides a brief update on the company's stock performance. No other details are provided.
A 9-Day Winning Streak Has Kymera Therapeutics Stock Up 17%
Kymera Therapeutics (KYMR) stock has seen a significant 9-day winning streak, increasing its market value by $1.7 billion and achieving a 17% gain. While the company boasts substantial revenue growth of 134.8% over the last twelve months, it also reports a considerable operating loss of -329.8%. The article suggests that investors should evaluate whether this growth justifies the losses, especially as such prolonged winning streaks are rare and require disciplined analysis rather than mere pursuit of momentum.
State of Wyoming Purchases New Position in Kymera Therapeutics, Inc. $KYMR
The State of Wyoming acquired a new position of 11,780 shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) valued at approximately $1.35 million during the second quarter. This comes as Kymera reported stronger-than-expected quarterly results with a significant revenue increase, although insiders sold a substantial amount of shares. Analysts maintain a "Moderate Buy" rating with an average price target of $125.65 for the stock.
T. Rowe Price Associates (KYMR) reports 8.6% stake in Kymera Therapeutics
T. Rowe Price Associates, Inc. has reported an 8.6% stake in Kymera Therapeutics Inc. (KYMR), holding 7,112,345 shares as of June 30, 2026. This information comes from an amended Schedule 13G/A SEC filing, indicating sole voting power over 7,086,948 shares and sole dispositive power over all 7,112,345 shares. Despite the filing, T. Rowe Price Associates explicitly denies beneficial ownership of these securities.
Kymera Therapeutics Stock 8-Day Winning Spree: Stock Climbs 14%
Kymera Therapeutics (NASDAQ: KYMR) stock has experienced an 8-day winning streak, resulting in a 14% increase in its stock price. The article highlights this significant recent performance for the company.
A 8-Day Winning Streak Has Kymera Therapeutics Stock Up 14%
Kymera Therapeutics (KYMR) stock has seen a significant 14% increase over an eight-day winning streak, boosting its market capitalization to approximately $11 billion. While the biotech company boasts rapid revenue growth of 134.8% over the last twelve months, it faces challenges with a -329.8% operating margin. The article suggests that such streaks highlight market attention and momentum, prompting investors to re-evaluate the underlying business fundamentals rather than simply chasing the trend.
Atlas Venture funds (KYMR) report 3.4% beneficial stake in Kymera Therapeutics
Atlas Venture funds have reported a collective beneficial ownership of 3.4% in Kymera Therapeutics (KYMR) through an amended Schedule 13G filing. This stake, totaling 2,847,541 shares, is split between Atlas Venture Fund X entities (2,384,685 shares) and Atlas Venture Opportunity Fund I entities (462,856 shares). The filing indicates that while these entities operate under common control, they expressly disclaim being a "group" for Section 13 purposes, and all reporting persons share voting and dispositive power over their respective shares, with no sole power.
Stifel Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $132
Stifel has reiterated its Buy rating for Kymera Therapeutics (KYMR.US) and maintained its target price at $132. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript
Kymera Therapeutics reported strong financial results for Q2 2026, with $65 million in collaboration revenue and a cash runway extending into 2029. The company highlighted significant progress in its clinical pipeline, including accelerated enrollment for its lead immunology program KT-621, with top-line data expected by year-end 2026. Kymera also announced leadership changes and reiterated its commitment to developing transformative oral medicines for inflammatory and autoimmune diseases.
Kymera Therapeutics (NASDAQ:KYMR) Sees Unusually-High Trading Volume - Still a Buy?
Kymera Therapeutics (NASDAQ:KYMR) experienced unusually high trading volume, with shares surging 185% to 2.09 million, despite a slight stock dip. The company reported better-than-expected quarterly earnings and a significant 465.2% year-over-year revenue increase. However, insider selling of approximately 3.6 million shares worth $387.6 million has raised some concerns, contrasting with analysts' "Moderate Buy" consensus.
California State Teachers Retirement System Increases Stake in Kymera Therapeutics, Inc. $KYMR
The California State Teachers Retirement System increased its stake in Kymera Therapeutics (NASDAQ:KYMR) by 23% in the first quarter, owning 56,282 shares valued at $4.7 million. Despite recent insider selling, analyst sentiment for Kymera Therapeutics remains positive, with a "Moderate Buy" consensus rating and an average price target of $125.65. The company recently exceeded quarterly expectations, reporting an adjusted loss of $0.62 per share and a significant revenue increase of 465.2% year-over-year.
Q3 EPS Forecast for Kymera Therapeutics Cut by Analyst
Brookline Capital Markets has reduced its Q3 2026 EPS forecast for Kymera Therapeutics to a loss of $1.31 per share, though it maintained a "Buy" rating. Despite the lowered forecast, Kymera reported a strong Q2, beating revenue and EPS expectations due to milestone payments and increased revenue. The company anticipates its cash runway will extend into 2029 and has several clinical catalysts expected by year-end 2026, though insider selling remains a notable activity.
Kymera Therapeutics, Inc. Stock 12‑Month Price Target Raised to $128.91, Implies 23% Upside
Kymera Therapeutics, Inc. (KYMR) has seen its average 12-month price target increased by analysts from $127.18 to $128.91, implying a potential 23% upside from its August 4th closing price. The consensus rating among 24 covering analysts remains "Buy," with 21 recommending Buy and 3 Hold.
Kymera Therapeutics Releases Q2 2026 Financial Results
Kymera Therapeutics reported its Q2 2026 financial results, posting a narrower-than-expected loss of $0.62 per share, surpassing the consensus estimate. The company's revenue surged to $65.0M, reflecting strong growth driven by its protein degradation platform. This performance indicates substantial year-over-year improvement and accelerating momentum for its clinical-stage pipeline.
Kymera Therapeutics (KYMR) Stock Faces A Revenue Durability Reckoning
Kymera Therapeutics (KYMR) saw its stock rise slightly after its Q2 earnings, reporting $65 million in collaboration revenue but ongoing net losses of over $60 million. The market views this as a steady update rather than a breakthrough, with investors questioning the durability of revenue heavily reliant on one-time partnership milestones against persistent high spending and losses. While the company highlights progress in its clinical pipeline and a cash runway into 2029, critics point to the dependency on collaboration revenue and substantial cash burn as significant concerns.
KYMERA THERAPEUTICS, INC. : CITIGROUP RAISES TARGET PRICE TO $135 FROM $120
Citigroup has increased its target price for KYMERA THERAPEUTICS, INC. (KYMR.O) to $135, up from the previous target of $120. This adjustment reflects Citigroup's updated outlook for the pharmaceutical company. The article, disseminated by Reuters, serves as a financial news update for investors.
KYMERA THERAPEUTICS, INC. : CITIGROUP RAISES TARGET PRICE TO $135 FROM $120
Citigroup has raised its target price for KYMERA THERAPEUTICS, INC. (KYMR.O) to $135 from $120. This adjustment reflects an updated outlook on the company's financial prospects by the analyst firm. The article, sourced from Reuters, reports this change in the target price.
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Kymera Therapeutics reported its second-quarter 2026 financial results, highlighting a strong cash position of $1.5 billion with a runway into 2029. The company also provided significant updates on its clinical pipeline, including the accelerated enrollment completion for its KT-621 BROADEN2 Phase 2b AD trial, with data expected by year-end 2026, and the initiation of Phase 1 trials for KT-485 by partner Sanofi. These developments underscore Kymera's progress in advancing oral small molecule degrader medicines for immunological diseases.
Kymera’s KT-621 atopic dermatitis trial closes enrollment six months early
Kymera's KT-621 atopic dermatitis trial, BROADEN2, has completed enrollment six months ahead of schedule, accelerating its topline readout to year-end 2026 and Phase 3 initiation to mid-2027. This rapid enrollment highlights potential confidence in the oral STAT6 degrader in a competitive therapeutic area. The company also has other clinical-stage programs advancing, backed by substantial cash reserves, positioning it to potentially run Phase 3 without external partnership.
Kymera Therapeutics (KYMR) Stock Faces A Revenue Durability Reckoning
Kymera Therapeutics (KYMR) reported Q2 earnings with a significant increase in collaboration revenue but continued substantial net losses. The company's stock saw a muted response despite meeting several execution milestones for its protein degrader platform, including advancements in clinical trials. Investors are now focused on the durability of the revenue and how long the company's cash reserves can sustain its high spending without consistent recurring income, especially as the revenue largely depends on one-time payments from partners.
Kymera Therapeutics Releases Q2 2026 Financial Results
Kymera Therapeutics (KYMR) reported Q2 2026 financial results, with a narrower-than-expected loss of $0.62 per share, beating the consensus estimate of a $0.73 loss. Revenue surged to $65.0M, reflecting strong growth from its protein degradation platform and strategic partnerships. The company's net loss was $61.2M, as it continues to advance its clinical pipeline, and Wall Street maintains a bullish outlook on the stock.
Press Release: Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Kymera Therapeutics has announced its financial results for the second quarter of 2026, alongside a business update. This release provides stakeholders with an overview of the company's financial performance and recent operational developments.
Earnings call transcript: Kymera beats Q2 2026 estimates on revenue surge
Kymera Therapeutics reported stronger-than-expected Q2 2026 results, surpassing revenue forecasts by over 100% and narrowing its adjusted loss. The biotech company highlighted significant progress in its clinical pipeline, particularly with the accelerated enrollment for its KT-621 atopic dermatitis study and the advancement of KT-579 into clinical trials for autoimmune diseases. Despite the revenue surge being driven by one-time collaboration payments, Kymera maintains a strong cash position extending into 2029, supporting its extensive clinical development plans.
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
Kymera Therapeutics (KYMR) reported a Q2 loss of $0.62 per share, beating the Zacks Consensus Estimate of a $0.64 loss, and revenue of $65 million, significantly surpassing the $11.48 million estimate. The company has outperformed the S&P 500 year-to-date with a 34.2% gain. Currently, the stock holds a Zacks Rank #3 (Hold) based on mixed estimate revisions.
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Kymera Therapeutics reported its second quarter 2026 financial results, highlighting significant progress in its clinical-stage programs. The company completed enrollment for its KT-621 BROADEN2 Phase 2b AD trial ahead of schedule, with data expected by year-end 2026 and Phase 3 trials planned for mid-2027. Kymera remains well-capitalized with $1.5 billion in cash, providing a runway into 2029.
Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q2 Collaboration Revenue $65.0M, vs. FactSet Est of $32.8M
Kymera Therapeutics, Inc. (KYMR) reported Q2 collaboration revenue of $65.0 million, significantly exceeding the FactSet estimate of $32.8 million. This positive earnings flash indicates strong performance in its collaboration agreements. The company's Q2 net loss also narrowed, further demonstrating improved financial results.
Will Kymera (KYMR) New CMO Hire Quietly Reframe Its Immunology Execution Story?
Kymera Therapeutics has appointed Terence Rooney, MD, as its new Chief Medical Officer, bringing extensive immunology drug development experience to the company. This hire could significantly impact the strategy for Kymera's oral immunology portfolio, particularly ahead of crucial Phase 2b readouts for KT 621. Investors are watching to see if Rooney's expertise can help Kymera convert its clinical science into commercial products, especially given the company's tight cash runway and high R&D spend.
Kymera earnings up next: Can degrader platform justify rally?
Kymera Therapeutics is preparing to report its second-quarter results, with analysts anticipating a loss of $0.73 per share on $31.17 million in revenue. Investors are keenly watching updates on its lead drug candidate, KT-621, for atopic dermatitis, as well as progress on other pipeline assets like KT-485 and KT-579, to determine if the company's protein degradation platform can sustain its recent stock rally. The market for targeted protein degradation is projected for significant growth, though some analysts suggest the stock may already be priced for success.
Kymera Therapeutics (KYMR) Could Be 23% Undervalued On Its New CMO Appointment
Kymera Therapeutics is in focus after appointing Terence Rooney, MD, as Chief Medical Officer, with the stock currently trading about 23% below the average analyst price target. The company's fair value is estimated at $127.52, driven by the potential of its immunology pipeline to offer biologics-like efficacy in oral form, which could improve margins and market share. However, risks remain regarding the success of its clinical trials and continued partner support, with its P/B ratio suggesting investors are paying a premium despite the company being loss-making.
Kymera Therapeutics (KYMR) Could Be 23% Undervalued On Its New CMO Appointment
Kymera Therapeutics (KYMR) recently appointed Terence Rooney, MD, as Chief Medical Officer, bringing new attention to its clinical development plans. Despite recent short-term share price weakness, analysts believe the stock is approximately 23% undervalued, with a fair value of $127.52. This valuation hinges on successful Phase II and III trials for their immunology pipeline and continued partner support, though the company currently trades at a premium P/B ratio compared to its biotech peers.
Kymera Therapeutics Inc (KYMR) Financial Health: Profitability & Balance Sheet Analysis
Kymera Therapeutics Inc (KYMR) currently holds a financial score of 8.29, ranking 46 out of 385 in the Biotechnology & Medical Research industry, indicating stable financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 55.50% to $34.37M, with net profit also rising by 5.57%. Despite some relevant data not being disclosed, its scores in Quality of Earnings, Operational Efficiency, and Growth Potential are high.
Kymera Therapeutics Inc (KYMR) Institutional Confidence
This article analyzes the institutional confidence in Kymera Therapeutics Inc (KYMR), which has a high institutional shareholding score of 10.00, ranking 1st in its industry. Institutional shareholding proportion increased by 8.46% quarter-over-quarter, with Baker Bros. Advisors LP and Fidelity Management & Research Company LLC being among the largest shareholders and increasing their holdings significantly.
Price-Driven Insight from (KYMR) for Rule-Based Strategy
This article provides a price-driven analysis of Kymera Therapeutics Inc. (NASDAQ: KYMR) for rule-based trading strategies. It highlights weak near and mid-term sentiment, despite a strong long-term outlook, with an exceptional risk-reward setup. The analysis includes AI-generated signals and institutional trading strategies across different risk profiles and time horizons.
Deutsche Bank Initiates Kymera Therapeutics(KYMR.US) With Hold Rating, Announces Target Price $120
Deutsche Bank has initiated coverage on Kymera Therapeutics (KYMR.US) with a Hold rating. The firm has set a target price of $120 for the company's stock.
KYMR Initiates Coverage By Deutsche Bank -- Rating Set to Hold
Kymera Therapeutics (KYMR) has received a "Hold" rating from Deutsche Bank with a price target of $120.00. GuruFocus indicates the stock is significantly overvalued by 334.5% compared to its GF Value™ of $24.23, and its GF Score™ of 46/100 points to below-average performance, particularly in profitability and growth. This cautionary stance is reinforced by substantial insider selling totaling $390.3 million over the past three months.
Deutsche Bank initiates Kymera stock with Hold on valuation concerns
Deutsche Bank has initiated coverage on Kymera Therapeutics (NASDAQ: KYMR) with a Hold rating and a $120.00 price target, citing valuation concerns despite the company's leading position in targeted protein degradation. The bank believes the stock's current price already reflects its base case for the lead asset KT-621, which is expected to perform similarly to Dupixent. Upcoming Phase 2b BROADEN2 study data for KT-621 in atopic dermatitis is a key catalyst, but Deutsche Bank sees a more balanced risk-reward profile for the stock heading into the readout.
Kymera Therapeutics to Report Q2 2026 Results on Aug 5
Kymera Therapeutics, Inc. will report its second quarter 2026 financial results on August 5, 2026, followed by a video conference call and webcast at 8:30 a.m. ET. The clinical-stage biopharmaceutical company will discuss its operational performance and pipeline development, particularly concerning its targeted protein degradation medicines for immunological diseases. Investors can register to access the live broadcast or find it on the company's website.
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
Kymera Therapeutics, a clinical-stage biopharmaceutical company, announced it will report its second quarter 2026 financial results on August 5, 2026. The company will host a video conference call and webcast at 8:30 a.m. ET on that day to discuss the results. Kymera Therapeutics is focused on developing oral small molecule degrader medicines for immunological diseases.
Kymera Sets Aug. 5 Webcast for Second-Quarter Results
Kymera Therapeutics (NASDAQ: KYMR) will report its second-quarter 2026 financial results on August 5, 2026. The company will host a video conference call and webcast at 8:30 a.m. ET on the same day. Investors can register for the live event or access a replay through the company's website.
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
Kymera Therapeutics (NASDAQ: KYMR) has announced the appointment of Terence Rooney, MD, as its new Chief Medical Officer, effective July 27, 2026. Dr. Rooney, formerly an immunology leader at Johnson & Johnson, will oversee the company's global clinical development strategy for its oral immunology portfolio. He succeeds Jared Gollob, MD, who is retiring after eight years but will remain as an advisor until the end of the year.
Eagle Health Investments LP Grows Position in Kymera Therapeutics, Inc. $KYMR
Eagle Health Investments LP has increased its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 7.0%, owning 145,816 shares valued at $12.1 million. This move is part of a broader trend of institutional investors growing their positions, despite significant insider selling totaling $390.3 million over the past 90 days. Analysts maintain a "Moderate Buy" rating for KYMR with an average price target of $122.64, following the company's stronger-than-expected quarterly revenue growth of 55.5%.
Press Release: Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
Kymera Therapeutics has announced the appointment of Terence Rooney, MD, as its new Chief Medical Officer, effective immediately. Dr. Rooney brings extensive experience from his previous role as Chief Medical Officer at Thrive Bioscience and over two decades in drug development across various therapeutic areas. This strategic hire aims to strengthen Kymera's clinical development capabilities as it advances its pipeline of protein degrader therapies.
KYMR Maintained by Guggenheim -- Price Target Raised to $135
Guggenheim maintained a 'Buy' rating on Kymera Therapeutics (KYMR) and raised its price target from $125 to $135, an 8% increase. Despite the positive analyst outlook, GuruFocus considers KYMR significantly overvalued with a GF Value™ of $24.14 against a current price of $110.04 and shows concerning insider selling activity. The company's GF Score™ of 46/100 indicates below-average performance, particularly in profitability and growth, suggesting investors should approach with caution.
Guggenheim raises Kymera Therapeutics price target on IRF5 program
Guggenheim has increased its price target for Kymera Therapeutics (NASDAQ: KYMR) to $135 from $125, maintaining a Buy rating, based on the potential of its IRF5 program (KT-579). The firm anticipates significant value if healthy volunteer data for KT-579, a protein degrader targeting the IRF5 master regulator protein, shows safe degradation above 90% in the second half of 2026. This target increase reflects a 15% probability of success for potential lupus sales, with higher probability leading to further increases.
Octagon Capital Advisors LP Reduces Position in Kymera Therapeutics, Inc. $KYMR
Octagon Capital Advisors LP significantly reduced its stake in Kymera Therapeutics by 20.6% in the first quarter of 2026, selling 110,000 shares but still retaining 425,000 shares valued at $35.4 million. Despite this reduction, Kymera Therapeutics reported better-than-expected quarterly results and holds a largely bullish rating from Wall Street analysts with a consensus price target of $122.64. However, company insiders sold over 3.6 million shares worth approximately $390.3 million in the latest quarter.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Rating of "Moderate Buy" by Brokerages
Kymera Therapeutics (NASDAQ:KYMR) has received a consensus "Moderate Buy" rating from 22 brokerages, with an average 12-month price target of $122.64, exceeding its current price of $110.57. Despite significant insider selling totaling $390.3 million over the past 90 days, the company recently surpassed Q4 earnings estimates, reporting a loss of $0.71 per share against an estimated $0.89 loss, with revenue up 55.5% year-over-year. Analysts anticipate a full-year loss of $3.28 per share for the biopharmaceutical company.
Form 4 Kymera Therapeutics Inc For: 27 July By Investing.com
This article reports on a Form 4 filing for Kymera Therapeutics Inc, dated July 27. It includes the company's stock symbol, KYMR, and notes a slight decrease in its share price. The content is presented without further financial details beyond the mention of the filing.
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
Kymera Therapeutics has appointed Terence Rooney, MD, as its new Chief Medical Officer, succeeding Jared Gollob, MD, who will retire after eight years. Dr. Rooney, formerly an immunology leader at Johnson & Johnson, will guide the clinical development strategy for Kymera's oral immunology portfolio. This appointment comes as the company advances multiple clinical programs and focuses on expanding oral treatment options for various immuno-inflammatory diseases.
